Increased H-FABP concentrations in nonalcoholic fatty liver disease: Possible marker for subclinical myocardial damage and subclinical atherosclerosis
| Autor: | Halil Erbiş, Nurcan Başar, Yaşar Tuna, Ömer Başar, Erdem Koçak, Derya Tok, Erdem Akbal, S. Köklü, M. Şenes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
fatty acid binding protein correlation analysis Subclinical myocardial damage Liver disorder Non-alcoholic Fatty Liver Disease cardiovascular disease insulin resistance Nonalcoholic fatty liver disease Carotid intima-media thickness glucose Subclinical infection Myocardial Stunning clinical article article biological marker unclassified drug female H-FABP Female Biological Markers liver enzyme Cardiology and Cardiovascular Medicine Fatty Acid Binding Protein 3 Adult medicine.medical_specialty metabolic parameters subclinical atherosclerosis protein H FABP B scan Fatty Acid-Binding Proteins Risk Assessment Sensitivity and Specificity Internal medicine medicine nonalcoholic fatty liver cross-sectional study Humans controlled study human fatty liver business.industry nutritional and metabolic diseases Reproducibility of Results arterial wall thickness medicine.disease Atherosclerosis digestive system diseases body mass enzyme linked immunosorbent assay Fatty Liver Endocrinology Increased risk glucose blood level Heart-type fatty acid binding protein Subclinical atherosclerosis protein blood level Feasibility Studies Metabolic syndrome business Biomarkers |
| Popis: | Aim: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder which is reported as the hepatic manifestation of metabolic syndrome with an increased risk of cardiovascular events. Patients with NAFLD are also at risk of future cardiac events independently of metabolic syndrome. The aim of this study was to examine serum concentrations of heart type fatty acid binding protein (H-FABP) in NAFLD and to investigate its correlations with metabolic parameters and subclinical atherosclerosis. Patients and methods: A total of 34 patients with NAFLD and 35 healthy subjects were enrolled in the study. NAFLD patients had elevated liver enzymes and steatosis graded on ultrasonography. Healthy subjects had normal liver enzymes and no steatosis on ultrasonography. H-FABP levels were measured using an enzyme linked immunosorbent assay (ELISA) method and correlations with metabolic parameters and subclinical atherosclerosis were examined. Subclinical atherosclerosis was determined with carotid artery intima-media thickness (CIMT) which was measured by high resolution B mode ultrasonography. Results: H-FABP levels were elevated in patients with NAFLD (16.3 ± 4.0 ng/ml) when compared with healthy controls (13.8 ± 2.1 ng/ml; p < 0.001). NAFLD patients had significantly higher CIMT than the controls had (0.64 ± 0.17 mm vs. 0.43 ± 0.14 mm, p = 0.009). The H-FABP concentrations were significantly positively correlated with body mass index (r = 0.255, p = 0.042), fasting blood glucose level (r = 0.300, p = 0.013), CIMT (r = 0.335, p = 0.043), and homeostasis model assessment-estimated insulin resistance (HOMA-IR; r = 0.156, p = 0.306). In multiple linear regression analysis, H-FABP levels were only independently associated with CIMT (p = 0.04) Conclusion: Serum H-FABP concentrations increase in patients with NAFLD. Our results may not only suggest that H-FABP is a marker of subclinical myocardial damage in patients with NAFLD but also of subclinical atherosclerosis, independent of metabolic syndrome and cardiac risk factors. © 2013 Urban & Vogel. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|